Kraig Biocraft Laboratories announced that its Project Atlas initiative has reached a critical milestone, a development that could accelerate the company’s transition from apparel‑focused spider‑silk products to high‑performance industrial and defense applications.
The milestone involves the creation of several new transgenic silkworm lines that combine multiple genetic elements into a single, integrated architecture. The new lines are now progressing through the company’s evaluation pipeline, and the platform is designed to produce entirely new classes of materials with enhanced strength and toughness beyond what is currently available in the market.
By expanding the spider‑silk platform into industrial and defense markets, Kraig Biocraft is positioning itself to capture higher‑margin revenue streams. The company’s leadership views Project Atlas as the most advanced molecular‑biology work ever undertaken in material science, a claim that underscores the technical depth required to engineer these new materials.
Founder and CEO Kim Thompson said the project “creates an advanced platform, where multiple components work in unison to achieve very specific material outcomes. That level of coordinated engineering has never been attempted before in spider silk or biomaterials, to our knowledge.” He added that the new platform will enable the company to meet the demanding performance requirements of defense and industrial customers.
The announcement was met with a positive market reaction, reflecting investor confidence in the company’s ability to commercialize the new materials and expand its product portfolio. Analysts noted that the milestone validates the company’s long‑term strategy to move beyond apparel and into higher‑value markets.
Kraig Biocraft is also scaling up production, with plans to deploy approximately one million proprietary silkworm eggs across three facilities in Vietnam. The company expects to reach up to 10 metric tons of cocoons per month starting in March 2026, a key step toward delivering the new materials to market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.